Ozmosi | Tramiprosate Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

Tramiprosate

Alternative Names: tramiprosate, nc-758, nc758, nc 758
Clinical Status: Inactive
Latest Update: 2026-04-14
Latest Update Note: News Article

Product Description

Mechanisms of Action: GABA Partial Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Bellus Health
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Alzheimer Disease|Cerebral Amyloid Angiopathy

Phase 2: Stroke|Cerebral Amyloid Angiopathy, Familial|Cerebral Hemorrhage

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00056238

 CL-758003

P2

Completed

Stroke|Cerebral Amyloid Angiopathy, Familial|Cerebral Hemorrhage

None

2023-12-15

Treatments

2006-006490-24

 2006-006490-24

P3

Completed

Alzheimer Disease

2010-04-19

2022-03-12

Treatments

2004-003435-31

 2004-003435-31

P3

Completed

Cerebral Amyloid Angiopathy|Alzheimer Disease

2007-12-14

2022-03-12

Treatments

NCT00314912

 CL-758017

P3

Unknown status

Alzheimer Disease

None

2023-12-15

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

04/14/2026

News Article

 Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer's Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois

04/07/2026

News Article

 Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism

03/10/2026

News Article

 Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen, Denmark

02/03/2026

News Article

 Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer's Patients

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions